Annual report pursuant to Section 13 and 15(d)

Accrued Expenses and Other Current Liabilities

v3.20.4
Accrued Expenses and Other Current Liabilities
 12 Months Ended
Dec. 31, 2020
Accrued Liabilities and Other Liabilities [Abstract]  
Accrued Expenses and Other Current Liabilities Accrued Expenses and Other Current Liabilities
 
Accrued expenses and other current liabilities as of December 31, 2020 and 2019 consisted of the following:
 
  December 31,
  2020 2019
Research and development expenses $ 4,939,095  $ 920,901 
Compensation and benefits 3,119,399  1,591,964 
General and administrative 771,381  360,016 
Sales and marketing 30,795  120,056 
Sales returns and allowances 1,793,811  2,284,175 
Medicaid rebates 118,655  118,271 
Lease liability, current 426,346  155,815 
Other 110,239  89,054 
Accrued expenses and other current liabilities $ 11,309,721  $ 5,640,252 

The increase in accrued research and development expenses to $4.9 million as of December 31, 2020 was driven by an increase in manufacturing, regulatory and clinical activities to support the advancement of our expanded and maturing pipeline.